CS0010
β-Secretase (BACE1) Activity Detection Kit (Fluorescent)
1 kit sufficient for 250 reactions
Synonym(s):
BACE1 Activity Detection Kit (Fluorescent)
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
Quality Level
usage
kit sufficient for 250 reactions
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... BACE1(23621)
Related Categories
Biochem/physiol Actions
BACE1 is a transmembrane protease responsible for the β site cleavage of the amyloid precursor protein (APP) to produce amyloid β peptide (Aβ). The accumulation of Aβ in the brain is a primary cause for the progression of Alzheimer′s. BACE1 is a target for inhibitor drug discovery.
Suitability
The kit provides all the reagents required for an efficient detection of BACE1 activity. It contains an enzyme to be used for screening for potential BACE1 inhibitors. The assay is based on the fluorescence resonance energy transfer (FRET) method in which the fluorescence signal enhancement is observed after substrate cleavage by BACE1.
Kit Components Only
Product No.
Description
- Fluorescent Assay Buffer 50 mL
- Stop Solution 15 mL
- Substrate (MOCA-SEV-NL-DAEFR-DNP-RR) 500 μL
- Assay Standard 140 μL
- BACE1 (β−Secretase) 300 units 100 μL
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Drug development research, 80(5), 655-665 (2019-05-03)
Beta-secreatse (BACE-1) and cholinesterases are clinically validated targets of Alzheimer's disease (AD), for which natural products have provided immense contribution. The multifaceted nature of AD signifies the need of multitargeted agents to tackle this disease. In the search of new
β-secretases as a target for the treatment of Alzheimer's.
Journal of Neuroscience Research, 70, 373-379 (2003)
Biomolecules, 10(4) (2020-04-05)
The treatment options for a patient diagnosed with Alzheimer's disease (AD) are currently limited. The cerebral accumulation of amyloid-β (Aβ) is a critical molecular event in the pathogenesis of AD. When the amyloidogenic β-secretase (BACE1) is inhibited, the production of
Fitoterapia, 130, 134-139 (2018-08-31)
Terrusnolides A-D (1-4), four butenolides were isolated from an endophytic Aspergillus from Tripterygium wilfordii. The structures of 1-4 were established by comprehensive spectroscopic analyses and electronic circular dichroism (ECD) calculation. It is interesting that 1 was a butenolide derived by
Cells, 8(5) (2019-05-22)
β-site APP-cleaving enzyme 1 (BACE1) initiates amyloid precursor protein (APP) cleavage and β-amyloid (Aβ) production, a critical step in the pathogenesis of Alzheimer's disease (AD). It is thus of considerable interest to investigate how BACE1 activity is regulated. BACE1 has
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service